Johnson & Johnson files application for new schizophrenia drug |
|
|
|
Published
:
Mon, 29 Oct 2007 13:55
|
NEW YORK (Thomson Financial) - Johnson & Johnson's pharmaceutical research division Monday said it had submitted a new drug application to the Food and Drug Administration for paliperidone palmitate, which treats schizophrenia.The company said the drug utilizes Elan's nanocrystal technology, and that upon approval, the drug will be marketed in the United States by Janssen LP.Johnson & Johnson is a consumer products company based in Titusville, N.J. Its stock closed Friday at $63.40.Ryan Vlastelicarv/pcCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
FDA approves J&J infection treatment 